Zhuhai Huahaikang Pharmaceutical Technology

Zhuhai Huahaikang Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Zhuhai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-value targets in oncology and metabolic diseases, leveraging its proprietary drug discovery platform to create first-in-class and best-in-class candidates. Its lead program, HHK-001, is a potent and selective Ubiquitin-specific protease 1 (USP1) inhibitor currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors. Additionally, the company is advancing a pipeline of oral small molecule GLP-1 receptor agonists for metabolic disorders such as obesity and diabetes. Huahaikang is led by an experienced management team with extensive backgrounds in global drug development and is supported by prominent venture capital investors.